Ization of targetfocused libraries for drug discovery is typically rationalized by invoking the savings realized in screening a smaller number of compounds with a higher en mass hit rate. This scenario can be true when the focused library is tasked with providing structures that act through mechanisms (and sites) similar to those affected by the populated prototypes. But it cannot account for allo